Dr. Martens (LON:DOCS) Given “Buy” Rating at Berenberg Bank

Dr. Martens (LON:DOCS)‘s stock had its “buy” rating restated by equities researchers at Berenberg Bank in a research note issued on Tuesday, Marketbeat Ratings reports.

Separately, Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Stock Performance

Shares of DOCS traded down GBX 9.50 during midday trading on Tuesday, hitting GBX 66.15. 5,113,644 shares of the stock traded hands, compared to its average volume of 1,825,940. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. Dr. Martens has a 1-year low of GBX 43.02 and a 1-year high of GBX 100.87. The business’s 50 day moving average price is GBX 76.53 and its two-hundred day moving average price is GBX 83.47. The firm has a market capitalization of £639.38 million, a PE ratio of 38.91, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last posted its earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Equities research analysts predict that Dr. Martens will post 2.5809394 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Robert Hanson purchased 96,000 shares of the business’s stock in a transaction on Friday, December 5th. The shares were purchased at an average price of GBX 79 per share, with a total value of £75,840. Insiders bought a total of 97,130 shares of company stock valued at $7,673,816 in the last ninety days. Corporate insiders own 2.79% of the company’s stock.

Dr. Martens News Summary

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Scaling back discounting should support gross margins and average selling prices, which can boost profitability if volumes don’t fall materially.
• Neutral Sentiment: The strategy signals a shift toward protecting brand value and margins rather than chasing revenue via promotions; outcome depends on consumer response and inventory execution.
• Negative Sentiment: The company guided to flat revenue for 2026, raising concerns about growth and prompting investor selling amid already-high leverage and a premium valuation. Dr Martens projects flat 2026 revenue as it scales back discounts

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.